These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34675486)

  • 1. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
    Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
    Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
    Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
    Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
    Moutasim MY; ElMeshad AN; El-Nabarawi MA
    Drug Deliv Transl Res; 2017 Jun; 7(3):450-459. PubMed ID: 28283842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
    Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
    Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets.
    Tayel SA; El Nabarawi MA; Amin MM; AbouGhaly MH
    AAPS PharmSciTech; 2017 Feb; 18(2):410-423. PubMed ID: 27038484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
    Tawfeek HM; Saleem IY; Roberts M
    J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
    Gowda V; Pabari RM; Kelly JG; Ramtoola Z
    Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs).
    Woyna-Orlewicz K; Brniak W; Tatara W; Strzebońska M; Haznar-Garbacz D; Szafraniec-Szczęsny J; Antosik-Rogóż A; Wojteczko K; Strózik M; Kurek M; Jachowicz R; Mendyk A
    Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug for enhanced dissolution: In-vitro optimization/in-vivo evaluation.
    Fouad SA; Malaak FA; El-Nabarawi MA; Abu Zeid K
    PLoS One; 2020; 15(12):e0244646. PubMed ID: 33382789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Dev Ind Pharm; 2017 May; 43(5):742-750. PubMed ID: 27534668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product.
    Chen Y; Feng T; Li Y; Du B; Weng W
    Pharm Dev Technol; 2017 Mar; 22(2):168-172. PubMed ID: 26654222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
    Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
    Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel sustained-release fast-disintegrating multi-unit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads.
    Aburahma MH; Hamza Yel-S
    Pharm Dev Technol; 2011 Aug; 16(4):316-30. PubMed ID: 20307250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
    Hamza Yel-S; Aburahma MH
    Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orodispersible Carbamazepine/Hydroxypropyl-β-Cyclodextrin Tablets Obtained by Direct Compression with Five-in-One Co-processed Excipients.
    Conceição J; Adeoye O; Cabral-Marques H; Concheiro A; Alvarez-Lorenzo C; Sousa Lobo JM
    AAPS PharmSciTech; 2020 Jan; 21(2):39. PubMed ID: 31897724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
    El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA
    Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression.
    Tafere C; Yilma Z; Abrha S; Yehualaw A
    PLoS One; 2021; 16(3):e0246648. PubMed ID: 33725014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.